Karyopharm Therapeutics Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. This is an annual report, not a standalone fourth-quarter results filing. Financial figures below are in U.S. dollars; financial statements were audited and received an unqualified opinion.
Business context
Karyopharm is a commercial-stage oncology company developing drugs that inhibit nuclear export. Its lead product, XPOVIO (selinexor), is marketed in the U.S. for multiple myeloma and diffuse large B-cell lymphoma (DLBCL). Development programs include selinexor and eltanexor in multiple myeloma, endometrial cancer, myelofibrosis and myelodysplastic syndromes.
Financial performance
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Product revenue, net | $98.4 million | $76.2 million | +29% |
| License and other revenue | $111.4 million | $31.9 million | +249% |
| Total revenue | $209.8 million | $108.1 million | +94% |
| Research and development expense | $160.8 million | $150.8 million | +7% |
| Selling, general and administrative expense | $143.8 million | $126.4 million | +14% |
| Operating loss | $98.3 million | $171.9 million | Loss narrowed |
| Net loss | $124.1 million | $196.3 million | Loss narrowed |
| Net loss per share | $1.65 | $2.72 | — |
| Net cash used in operating activities | $107.1 million | $160.2 million | Cash use decreased |
Revenue growth reflected 29% higher XPOVIO sales, following U.S. approval of an earlier-line multiple myeloma indication, and $75.0 million of upfront Menarini license revenue. Antengene contributed $29.3 million of development/regulatory milestone revenue. Reported cost of sales was $3.4 million; the resulting product margin is not a reliable indicator of normalized economics because some XPOVIO manufacturing costs were expensed before approval.
Financial position and liquidity
- At year-end, cash and cash equivalents were $190.5 million and short-term investments were $38.2 million; cash, cash equivalents and investments totaled $228.6 million. Including restricted cash, cash resources were $235.6 million.
- Current assets were $275.6 million against current liabilities of $73.7 million. Total liabilities were $385.0 million, and stockholders’ equity was negative $79.7 million.
- Debt included $169.3 million carrying value of 3.00% convertible notes due 2025 (principal $172.5 million) and a $133.0 million deferred royalty obligation on the balance sheet. The royalty financing carries an effective interest rate of 18% at year-end.
- Management stated that available cash, cash equivalents and investments were expected to fund current plans for at least 12 months from issuance of the financial statements. The company reported an accumulated deficit of $1.2 billion and has not achieved profitability.
Material changes, outlook and risks
- Commercial and licensing: U.S. XPOVIO product revenue rose 29%. Menarini’s $75.0 million upfront payment was a significant, non-recurring contributor to FY2021 revenue; management expected license and other revenue to decrease in 2022. Menarini may also owe up to $202.5 million in milestones, tiered royalties, and reimbursement of qualifying development costs, subject to contract terms.
- Management outlook: The company expected XPOVIO product revenue to increase in 2022, R&D expense to decrease as programs were prioritized, and SG&A expense to increase to support commercial activity. No quantified 2022 revenue or earnings guidance is provided in the supplied filing text.
- Endometrial cancer: SIENDO reported median PFS of 5.7 months with selinexor versus 3.8 months with placebo in the overall population (eCRF HR 0.70; p=0.0486). An alternative IRT-based analysis gave HR 0.76 and p=0.1266. The p53-wild-type subgroup showed median PFS of 13.7 versus 3.7 months, but this was exploratory, with no alpha allocated. After the February 2022 FDA meeting, management said the trial results were unlikely to support an sNDA approval and planned a new randomized study in p53-wild-type patients.
- Regulatory: The DLBCL indication remains under accelerated approval, with confirmatory studies required. EMA review of a BOSTON-based variation was ongoing; inspection reports raised questions and findings that the company said it had addressed, but EMA acceptance was not assured.
- Funding and debt: Continued losses mean additional financing may be needed. The HCR royalty agreement imposes covenants and repayment provisions, including potential accelerated payments and collateral rights in specified events. Convertible notes create future repayment, conversion and potential dilution risks.
- Other exposures: The company identified competition, drug tolerability and adoption, reimbursement and pricing pressure, COVID-19-related disruption, reliance on third-party manufacturers (including a single-source supplier), and regulatory and clinical-trial uncertainty as material risks. A securities class-action dismissal was appealed; a related derivative suit remained stayed.
Key facts for investors to verify
- How much of FY2021 revenue growth came from recurring XPOVIO sales versus one-time upfront and milestone license revenue, and whether 2022 product growth offsets the expected license-revenue decline.
- Updated XPOVIO sales trends, uptake in earlier-line myeloma, product pricing and reimbursement, and normalized cost of sales after previously expensed inventory is used.
- Final SIENDO analyses and the design, timing, cost and regulatory path for the planned p53-wild-type trial.
- Progress and inspection outcomes for the EMA BOSTON variation and completion of required DLBCL confirmatory studies.
- Cash burn and runway relative to the $172.5 million note principal, HCR repayment terms and covenants, and potential dilution or financing needs.